DiscoveRx® is a fast growing innovative company that develops, manufactures, and commercializes reagents and complete assay kits for the drug discovery and screening markets. Our products, biochemical and cell-based assays, enable customers to improve research productivity and effectiveness, thus accelerating the discovery and development of new drugs.

Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in California with offices in England, Germany, and France. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study major drug target classes such as GPCRs and kinases.

DiscoveRx assay solutions are based on our core proprietary Enzyme Fragment Complementation (EFC) technology that is well established in clinical diagnostics and now further enhanced to provide unique solutions to drug discovery research. EFC technology is a proven, established screening technology in most major pharmaceutical companies and our EFC-based HitHunter™ cAMP assays are the market leader in GPCR screening applications. PathHunter™ technology, an adaptation of EFC technology, is an innovative and comprehensive assay system that enables in vivo cell-based assays for pathway profiling and screening. Through our core HitHunter™, PathHunter™, and EFC technologies, DiscoveRx is able to offer assay solutions for every major class of drug target, including GPCRs, kinases, proteases, nuclear hormone receptors, transcription factors, and secreted proteins.

DiscoveRx – Simple Solutions for Complex Biology

Last Updated: 03-14-2006